Once-a-day acne pill shows 40-week safety in 240 Chinese patients

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne USA – English APAC – English APAC – Traditional Chinese

–  Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study –  The exceptional efficacy of denifanstat (ASC40) observed in the Company’s previously reported placebo-controlled Phase III trial coupled with a favorable safety profile in two Phase III trials provide a potential major break-through for the treatment of acne –  New Drug Application for …

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

–  Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study –  The exceptional efficacy of denifanstat (ASC40) observed in the Company’s previously reported placebo-controlled Phase III trial coupled with a favorable safety profile in two Phase III trials provide a potential major break-through for […]

Once-a-day acne pill shows 40-week safety in 240 Chinese patients

China's regulator accepted an acne NDA for denifanstat after Phase III trials showed favorable 40-week safety, backing its potential as a new treatment.